Regeneron Pharmaceuticals Inc. (REGN) said that the Phase 3 PANORAMA trial evaluating Eylea (aflibercept) Injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint and key secondary endpoints.
from RTT - Biotech https://ift.tt/2PkwhDv
via IFTTT
No comments:
Post a Comment